PDCD1 and neoplasm: Specifically, enrichment of the immune system pathways “cancer immunotherapy by PD1 blockade,” “T cell antigen receptor TCR signaling pathway,” and “interactions between immune cells and microRNAs in tumor microenvironment” reflect the activity of this regimen (Figure 2, C and D).